



## Workshop

# REMEDI4ALL:

# What's in it for funders?

Learn and discuss how REMEDI4ALL & the funders network can support your funding activities in drug repurposing.

Learn more: <https://remedi4all.org/events/>



5 July 2023



12:00-14:00 CEST



Online



The REMEDI4ALL project has received funding from the European Union's Horizon Europe Research & Innovation programme under grant agreement No 101057442.



# Welcome

---

Heleen van der Meer, PharmD | PhD

Senior programme manager international drug repurposing



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

# Housekeeping rules

- Workshop will be recorded for internal use only
- Slides will be shared
- Please turn microphone off
- We will ask for your input (funders) via polls
- Questions can be asked via chat





Time	Topic
12.00-12.05	<b>Welcome</b> Chair: Heleen van der Meer (ZonMw)
12.05-12.30	<b>Introduction REMEDi4ALL and funders network</b> Anton Ussi (EATRIS) & Heleen van der Meer (ZonMw)
12.30-12.40	<b>How do you repurpose? REMEDi4ALL's training programme for the whole repurposing ecosystem</b> Rick Thomson (BEACON: for rare diseases) + your input
12.40-12.50	<b>Introduction to the REMEDi4ALL Funding Decision Tool</b> Marcell Csanadi (Syreon Research Institute) + your input
12.50-13.00	Q&A - break
13.00-13.20	<b>Funding drug repurposing: barriers, solutions &amp; incentives needed</b> Heleen van der Meer (ZonMw)
13.20-13.45	<b>Panel discussion</b> Moderated by Pan Pantziarka (Anticancer Fund)  Panellists: Joanna Davidge (LifeArc) Teun Grooters (Arega Medical) Sagair Hussain (DEBRA) Sarah Puddicombe (National Institute for Health and Care Research Coordinating Centre (NIHR CC))
13.45-14.00	<b>Next steps for the funders network &amp; closing</b> Heleen van der Meer (ZonMw) + your input

# Who is in the room?



Type of funder





# THE EUROPEAN PLATFORM FOR MEDICINES REPURPOSING

Anton Ussi - Operations & Finance Director, EATRIS

**eatris**

European infrastructure  
for translational medicine



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

# WHY DRUG REPURPOSING?

## CONCEPT

- Finding new therapeutic uses for existing medicines.

## RATIONALE

- Leverage knowledge previously generated on safety and effectiveness of a known drug to explore new indications.


## POTENTIAL

- Lower barrier to enter drug development: less costly and quicker
- Bring (much needed) new therapeutic options to patients, faster
- Ideal collaborative model for academics, SME and patients

→ More efficient research with high social impact



# WHY CREATE A DRUG REPURPOSING PLATFORM IN EUROPE?



- Huge interest and activity in repurposing
  - But very fragmented
  - No single entity can do it all



- First EU stimulus
- Mandate: defragment; create accessible eco-system



# OUR VISION




An EU research and innovation ecosystem that facilitates fast, cost-effective and patient-centric development and implementation of repurposed medicines, meeting high unmet medical needs in any disease area

# TWO OPERATIONAL GOALS



Build a complete, standardised and accessible platform served by experts in all facets of the medicine repurposing journey



Create a think-tank that develops and advances drug repurposing policy

# THE REMEDIa4LL WORKPLAN

## WP10 – CLINICAL & NON-CLINICAL DEMONSTRATORS

### TRANSVERSAL

---

WP1 – PATIENT  
& USER ENGAGEMENT  
(CO-CREATION)

WP2 – OPERATIONS  
PROJECT PROFILING  
& (REGULATORY PLANNING)

WP3 – TRAINING  
& CAPACITY BUILDING

### DISCOVERY

WP4 – IN SILICO TOOLS

WP5 – IN VITRO SERVICES

### DEVELOPMENT

WP6 – PRECLINICAL  
DEVELOPMENT  
& VALIDATION

WP7 – CLINICAL  
DEVELOPMENT  
& IMPLEMENTATION

### PRACTICE

WP8 – IMPROVING MARKET  
ACCESS ENVIROMENT

WP9 – FUNDERS NETWORK &  
RESEARCH FUNDING POLICY

WP11 – BUSINESS PLAN & COMMUNICATION

WP12 – INTERNATIONAL NETWORK

WP13 – PROJECT MANAGEMENT

# A COMPLETE, ACCESSIBLE VALUE CHAIN



## Pillar 1: Assembling EU's 'Bricks and Brains'

### ASSEMBLE THE BRICKS & BRAINS



CANDIDATE PROJECTS



PRIORITISATION & SELECTION



USERS ONBOARDING



PATIENT CHAMPIONS



REPURPOSING DEVELOPMENT TEAMS



DEVELOPMENT PLAN



PROJECT EXECUTION

### ENGAGE USERS & COMMUNITIES

### DESIGN & EXECUTE PROJECTS

### TOOLS & ACTIVITIES



PORTAL



CATALOGUE OF SERVICES



TRAINING



ACADEMIC-DRIVEN DEMONSTRATORS



PROVIDERS MARKETPLACE



FRAMEWORK AGREEMENT



FUNDING RADAR



QUALITY & REPRODUCIBILITY



DATA MANAGEMENT

### DEMONSTRATOR PROJECTS


- Covid-19
- Metastatic pancreatic ductal adenocarcinoma
- Multiple Sulfatase Deficiency
- Osteogenesis imperfecta

patient-oriented, rigorous study and execution


# BRINGING ALL STAKEHOLDERS TOGETHER



## Pillar 2: Future-proofing the repurposing process



STAKEHOLDERS FORUM



POLICY BOARD



ETHICS BOARD



FUNDERS NETWORK



REPURPOSING ACADEMY



ANNUAL CONFERENCE



INTERNATIONALISATION STRATEGY / NETWORKING



A PLATFORM THAT:

IS TESTED AND SUSTAINABLE • IS A COMPLETE VALUE CHAIN • DEVELOPS HIGH VALUE REPURPOSED MEDICINES  
HAS A VIBRANT COMMUNITY OF PRACTICE • IMPROVES FRAMEWORK CONDITIONS



RESEARCHERS



PATIENTS



HEALTH CARE SYSTEM



PAYERS



PUBLIC SECTOR



PHARMACEUTICAL INDUSTRY



POLICY-MAKERS

COMMUNITY OF PRACTICE

# REMEDi4ALL PARTNERS & ASSOCIATED PARTNERS


## Scientific coordination & mgt



## Patient engagement



## Health technology & regulatory



## Research Institutions




## Clinical Research Hospitals



## SME & Industry



## Funders



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442.

[remedi4all.org](http://remedi4all.org) #R4ALL #REMEDi4ALL

# REPURPOSING CONCIERGE



Launched March 20<sup>th</sup>, > 50 requests since then!

~ 4 requests per week

30-min introductory call with all requesters!


If request involves PE, EURORDIS/Beacon join first discussion




# Repurposing Concierge activity



## Audience




## Type of support requested





# Onboarding of projects



# patient engagement – essential co-creators

PATIENT'S  
NEEDS

## PATIENT ENGAGEMENT

PATIENT'S CARE

### DISCOVERY PHASE

- ① Learn about the disease and understand the **condition from a patient's perspective**
- ① Start partnering with patients and develop your **research question** based on patient's needs and priorities.
- ① Clearly define and agree on the **collaborative research goals** and future steps
- ① Develop a **research methodology** based on patient inputs or PROs

### PRECLINICAL DEVELOPMENT

### CLINICAL DEVELOPMENT

- ① Develop **patient relevant outcome measures**
- ① Design the clinical **trial protocol**
- ① Design **patient facing materials**
- ① Develop **recruitment and retention strategy**

### APPROVAL AND MARKET ACCESS

- ① Patients serve on **EMA Advisory Committees**, contribute to benefit/risk discussion, and as Patient Representatives.
- ① Patients provide input on **Risk Evaluation** and mitigation strategies and feedback on Phase IV studies.
- ① Patients provide evidence to **support HTA**

### POST APPROVAL SURVEILLANCE

Including multi-stakeholder meetings with funders

# Patient Engagement RESOURCE CENTRE

Find out more on  
[patient-engagement.eu](https://patient-engagement.eu)



# THE TEAM





# THANK YOU



[remedi4all.org](https://remedi4all.org)



[twitter.com/REMEDI4ALL](https://twitter.com/REMEDI4ALL)



[linkedin.com/company/remedi4all](https://linkedin.com/company/remedi4all)



[fb.me/REMEDI4ALL](https://fb.me/REMEDI4ALL)



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. This presentation reflects only the author's view. The EU is not responsible for any use that may be made of the information it contains.

**#R4ALL #REMEDI4ALL**



# Funders Network

---

Heleen van der Meer, PharmD | PhD

Senior programme manager international drug repurposing



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

# Aim of the funders network



*A dynamic international network comprising diverse funders who are committed to driving drug repurposing forward.*



*An inclusive forum for discussion (think tanks), where we encourage you to share your funding perspective and actively engage in conversations surrounding policy matters and potential solutions to enhance the field.*




*Reduce fragmentation of the drug repurposing funding landscape, facilitate coordination of funding activities, create new funding streams and identify opportunities for joint calls.*




*We hold annual meetings where we exchange best funding practices.*

> 50 funders interested to join the funders network






> 50 funders interested to join the funders network



# Activities so far



# Your expectations of the funders network



find solutions for funding barriers together



# What's in it for funders?

## *Be part of*

*a strong and impactful international network comprising diverse funders who are committed to driving Drug Repurposing forward*

- **a marketplace**
  - Find like-minded funders (e.g. funding radar, co-funding)
  - Find projects to fund/invest in (e.g. multi stakeholder meetings, repurposing concierge)
  - Share best funding practice (e.g. during workshops, innovative funding models)
  - Learn from other funders (e.g. training, funding decision tool)
- **a think tank**
  - Engage in conversations surrounding policy matters (e.g. work package 8 on market access, policy board)
  - Work on finding solutions for funding barriers

Show your organisations' commitment to improve drug repurposing

Make your vision for the future of drug repurposing count

Receive the latest news on the REMEDI4ALL platform and funders network



# How do you repurpose?

REMEDI4ALL's training programme for the whole repurposing ecosystem

Rick Thompson – *CEO, Beacon: for rare diseases*



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

# Why repurpose?

- ① Repurposing offers a potentially **faster** route to **patient impact**.
- ① Repurposing offers a **lower barrier** of entry to drug development, making research in areas of low interest possible.
- ① Repurposing is an ideal **collaborative model** of drug development – academics, SMEs, and patient groups can all have a big impact.

# Why train the repurposing community?




Build a complete, visible and accessible value chain for patient-centric repurposing



Create new ways of thinking about repurposing across all stakeholders



Drive policy, regulation and access changes through collaborative education



# The repurposing pathway



## Drug Repurposing Pathway

Collaborative models of research

Funding

Project Management

Patient Engagement

Identifying Repurposing Opportunities

Pre-clinical Development


Clinical Development

Regulation

Business Models & Health Economics

Target Product Profile (TPP)

Patient Access






# Transform an experimental hypothesis into a new therapy



The core aim of repurposing within REMEDI4ALL is **to get a new treatment to a patient**, not a new paper.




This requires a diverse range of skills and knowledge beyond the hypothesis testing skills that scientists are traditionally trained for.




This is the **biggest barrier to successful repurposing**. We think improving the skills of researchers in this area, can generate more impact from your funding!


# Project Management for Scientists



How to fund each step



How to choose a good manager for your project



Who project leads should be talking to and when



Data – what is good data?



How to effectively communicate with collaborators



Regular re-focus on who the project is for



Expectation management

# Training structure



	Level	Main training type	Delivery route	Audience
1	Why repurpose?	Why is repurposing important? Case studies and success stories. Aim to win people to the cause.	General communications, conference presentations	Industry, General public, regulators, funders, patient organisations
2	How to repurpose with patient impact	The core training curriculum, including the TPP, repo pathway, and project management	Repurposing academy, e-learning resources	Academics, patient organisations, champions, users
3	Repurposing techniques	Specific training on scientific tools and techniques. More technical knowledge.	Webinars, e-learning content, sign posting, and user mentoring	Industry, specific branches of academia or life scientists with a specific interest in repurposing

# Training and support for funders



Our core training should help more researchers propose repurposing projects with a chance to reach market – good for funder impact.

*Funder training ideas...*

**What would you  
like to see?**



# Live poll results – 33 answers

What type of training would you like to receive to support your efforts in drug repurposing?



# Training and support for funders



Our core training should help more researchers propose repurposing projects with a chance to reach market – good for funder impact.

## *Funder training ideas...*

- ① Why fund repurposing research?
- ① The value and implementation of great patient engagement in drug repurposing programmes
- ① What are the indicators of a good repurposing project?
- ① What are the routes to market, and patient impact in drug repurposing?
- ① What makes a good repurposing PI? Finding projects with the ingredients for success.

We'd love to organise a dedicated training workshop for the REMEDI4ALL funders network soon...



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union, who cannot be held responsible for them. This presentation reflects only the author's view. The EU is not responsible for any use that may be made of the information it contains.

# How will we deliver training?



In person  
training  
workshops

E-learning  
resources

General  
communication


Webinars

Podcast



# Poll results – 40 answers

What training formats would you be happy to engage with?



# Our questions to you...



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union, who cannot be held responsible for them. This presentation reflects only the author's view. The EU is not responsible for any use that may be made of the information it contains.




# Live poll results – 14 answers

What would be the best way to target training to the funder's community?




## Live poll results – 32 answers

Do you currently require patient engagement to be part of your funding applications?



## Live poll results – 37 answers

Do you think the REMEDI4ALL training programme would increase the success of the projects you fund?





# Introduction to the REMEDI4ALL Funding Decision Tool

---

Marcell Csanadi, PhD - Health economist

**syreon**  
Research Institute



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

# Introducing



- Syreon aims to support **socially driven evidence-based decision-making** in healthcare through
  - involving key stakeholders,
  - facilitating educational activities and
  - utilizing the international networks to generate and disseminate evidence
- Syreon provides **expertise in health economic and health policy research** supporting partners throughout the lifecycle of health technologies

## Main areas of research services:

- Evidence synthesis
- Data analysis
- Epidemiology & Public Health
- Economic value
- Outcomes research
- Health policy
- Patient policy
- Pricing & Reimbursement

# REMEDI4ALL Funding Decision Tool



## Major activities in the funding work package:

1. Create a vibrant (DR) funding network
2. Funding models – Develop new solutions, develop a funding radar
3. Standardized tool for the assessment of drug repurposing candidates

## Who is intended to use the developed tool?

- **REMEDI4ALL consortium:** Support the project selection for onboarding + Support the future funding activities
- **Members of the funders network (depending on experience and need):**
  - Highlight new perspectives or criteria of the assessment
  - Provide alternative methods for assessing certain criteria
  - The REMEDI4ALL tool can provide a basis for their assessment (for funders with diverse background)



# How do you currently assess the value of drug repurposing candidates?




This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union, who cannot be held responsible for them. This presentation reflects only the author's view. The EU is not responsible for any use that may be made of the information it contains.

## Live poll results – 35 answers

If your organization is dealing with funding drug repurposing projects, to what extent do you see room for improvement in how you currently assess the value of drug repurposing candidates?

2.2



# Exploratory work to propose a standardized tool for the assessment



## Phase 1

1. Review the scientific and grey literature about funding drug repurposing
2. Collect published materials from funders who are part of the funding network (e.g. websites, other documents)
3. Conduct follow-up discussions with funders who were interviewed by ZonMw



Identification of value assessment criteria  
Evaluation process of the assessment criteria

## Phase 2

1. Propose a concept for the tool based on the collected information
2. Organize a challenge meeting with active fundres from the funding network



A final concept ready to be developed

**Let's hear about the criteria that you think are the most important...**



# Live poll results – 56 answers

Please list the 3 most important funding criteria when evaluating a drug repurposing project.



# Identification of assessment criteria



We are currently conducting a transparent and documented procedure to identify relevant assessment criteria for the tool

Full list of assessment criteria from literature and funders

- Patient engagement
- Unmet medical need
- Financial return on investment
- Productivity loss / gains
- Change in behavior of society
- Innovation
- ...

Clear definition is given for each criterion

+

Based on the definition, the criteria relevant for drug repurposing (yes / no)

- ...

Evaluating whether it is possible to measure, or specific metrics can be related to the criteria (yes / no)

- ...

Standardized tool with a list of measurable criteria for the assessment of drug repurposing candidates

- Funders will be able to select criteria that are relevant for their assessment
- Recommendations will be provided for measurement and required input data


# Should we measure the expected return on investment?



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union, who cannot be held responsible for them. This presentation reflects only the author's view. The EU is not responsible for any use that may be made of the information it contains.

# Live poll results – 38 answers

If there was a tool available for evaluation with two perspectives - financial return on investment and societal return on investment - which one would your organisation prefer to apply before making a funding decision?







## Q&A - break

---

Dunja Huijbers

Senior programme manager (Drug Rediscovery)



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.



# Funding drug repurposing: barriers, solutions & incentives needed

---

Heleen van der Meer, PharmD | PhD


Senior programme manager international drug repurposing




This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.

# Many of **you** shared the **barriers** you face in funding drug repurposing, possible **solutions** and/or **incentives** needed from your **perspective** via

- online surveys (n=43)
  - online interviews of 60 minutes (n=20)
- interviews were transcribed
- coded in Atlas.ti to identify barriers, solutions & incentives



# Barriers



Collaboration  
and network  
building  
(n=56)

## Barriers



Pharmaceutical  
company does not  
provide drug for  
clinical trial

Long timelines for  
contracts and  
agreements

Different funder  
interests hinder  
collaboration


Co-funding across  
borders

Pharmaceutical  
company needed  
for label extension

State aid rules  
hinder funding of  
public-private  
collaborations

Pharmaceutical  
company does not  
provide (safety)  
data

*“...if there's no common ground, that partnership is not going to happen.”*



## Barriers



Researcher does not know how to perform a DR trial

Capacity limits

Lack of knowledge on registration process

Lack of knowledge on how to get scientific advice

Lack of knowledge on translating pre-clinical research into clinical research

Funder lacks experience with DR trials

*“...we notice researchers and research institutes have insufficient knowledge about how to get repurposed drugs to the patient.”*

Market authorization  
(n=60)

## Barriers



Academic trials versus regulatory process

Regulatory process does not fit DR products

Different regulatory processes in different countries

Off-label use

High costs & long timelines scientific advice

Challenge to get the regulator on board

Need for label extension

*"How do we get to a situation where we can run affordable clinical trials so that it is not costing 20 million to test a drug that's already approved?"*

Market access,  
HTA, pricing and  
reimbursement  
(n=46)

## Barriers



Market withdrawal  
due to low drug  
prices

Add-on is not  
allowed

Reimbursement in  
different countries

Unclear market  
access landscape

Small market size

High drug prices

No patient access

No transparency  
on real market  
costs

Marketing of drug  
costs money for  
MAH

**Generic pricing  
framework does  
not fit DR**

No reimbursement  
for off-label use

Low willingness to  
pay

*“Pricing is always key, societies are asking for innovation but do not want to pay extra for additional value.”*



Valorisation  
(n=75)

## Barriers

Academic output  
(publications)  
versus  
valorisation

No return on  
investment

Lack of scalability

Lack of data  
protection

Off-label use

Generic  
substitution

One party takes  
all the risk

*“....without a proper business case, you'll never find a fool to invest in repurposing for cheap medicines again.”*

Tools &  
instruments  
(n=52)

## Barriers

Reformulation or  
re-dosage needed  
for trial

No access to  
placebo for  
clinical trial

Difficult patient  
recruitment

Limited funding  
available for DR

Drug is not  
manufactured  
anymore

(Safety) data not  
available or lacks  
quality

Drug not  
accessible for  
clinical trial

*“...there is no lack of ideas by the researchers, but there is a shortage of funding.”*

Other  
(n=41)

## Barriers

Ethical issues

DR research is not  
always called DR

DR is not seen as  
an important  
theme

No funding stream  
dedicated to DR

Lack of high-  
quality proposals

Lack of DR  
funding  
applications


Lack of industry  
interest

Field of DR is in  
starting phase, the  
process takes  
time

Political decisions


*“...a barrier is the fact that we don't have a channel specifically for drug repurposing, which makes it also a little bit hidden...”*

# Proposed solutions and incentives needed



*“... a **specific / clear / easier regulatory pathway** for repurposed medicines ...”*

*“ ... the safety profile of these products [...] is known especially if you take lower doses [...] you would **only need confirmation of efficacy**. [...] in my opinion, you could do some kind of **conditional approval based on the phase 2 study** ...”*



# Proposed solutions and incentives needed



“... as a *company* you still like to *make a bit of money* on it because otherwise no one's going to invest in you ...”


“... *accelerated reimbursement* pathway and more clarity for repurposed medicines - *cut away time* that is not attributing to effectiveness/safety but *adds costs* ...”

“... pricing level for repurposed drugs should be set high enough to *recuperate the investments* needed to develop a second/third indication with the same API ...”

“*pricing level* should be *differentiated between first indication and repurposed indication*, e.g. for a certain time period or for a certain supplier that developed the repurposed indication”

Get (realistic) return on investment	tax benefits	subsidies and/or equity investment and/or non-dilutive loans from government	harmonization of EU procedures regarding market access of value-added medicines
other reimbursement criteria	hidden prices	government pays generic company for label extension	price & reimbursement guidelines across EU countries must guarantee a better ROI
protection for x period	premium on generic price	scalability to other countries	
reward for innovation created	indication on prescription		

# Proposed solutions and incentives needed



*“... developing **partnering models** that bring **pharma companies** and their assets together with **academics** and their ideas for indications ...”*

*“... make **data publicly available** of products that **do not reach the market**, so data can be used for other indications ...”*

*“... accessing live assets for rare disease development in **parallel with the primary indication**, to **multipurpose the asset while under development** instead of waiting until it is on the market ...”*

pharma support and commitment if trial is successful

get pharma company support for repurposing trials which are outside their development plans

early engagement with pharmaceutical company to ensure supply of drug

involve pharma representatives in project monitoring

set up contractual frame (one that is recognized by pharma) to facilitate negotiation with pharma


group together - funding whole lifecycle - awareness for whole lifecycle

find like-minded co-funders

creation of transnational framework for DR research funding

sharing publicly funded data package with generic company for label extension – stable price in return

# Proposed solutions and incentives needed



*“... always think of **implementation**, once the study has completed it has to be able to be directly implemented ...”*

*“... somebody has to **take a risk** in the government field and if you're not doing that, then it's really ready to fail ...”*

willingness to do something - not looking to someone else to move

DR on political agenda  
improve image of DR by showing statistics

an academic pharma company to produce generics for publicly funded trials

repurposing toolkit to help academic/charity/patient group-led repurposing projects

erect a government supported institute to develop repurposed drugs

having a platform for drug repurposing where all stakeholders are involved



# REMEDI4ALL and the funders network are here to support you overcome funding barriers



## *Be part of*

*a strong and impactful international network comprising diverse funders who are committed to driving Drug Repurposing forward*

- **a marketplace**
  - Find like-minded funders (e.g. funding radar, co-funding)
  - Find projects to fund/invest in (e.g. within network, repurposing concierge)
  - Share best funding practice (e.g. during workshops, innovative funding models)
  - Learn from other funders (e.g. training, funding decision tool)
- **a think tank**
  - Engage in policy discussion (e.g. work package 8 on market access, policy board)
  - Work on finding solutions for funding barriers





## Panel discussion

---

Pan Pantziarka, PhD

Programme Director Drug Repurposing



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.



# Panellists

Joanna Davidge

LifeArc

Teun Grooters

Arega Medical

Sarah Puddicombe

National Institute for Health and Care Research  
Coordinating Centre (NIHR CC)

*From your perspective:*

*where should we as REMEDi4ALL/funders network focus in terms of solutions to the barriers that were just mentioned?*



## Next steps for the funders network

---

Heleen van der Meer, PharmD | PhD

Senior programme manager international drug repurposing



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101057442. Views and opinions expressed in this presentation are those of the author(s) only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains.



# Next steps for the funders network

- Network is currently being created – charter will follow
- Receive updates via our newsletter – subscribe via <https://remedi4all.org/funders/>
- You may be invited for further discussion in think tanks about specific topics
- Repurposing concierge is open for you
  
- Future meetings
  - MSM pancreatic cancer 14 Nov 2023
  - Workshop investment decision tool - TBA
  - Annual REMEDI4ALL conference on 6-7<sup>th</sup> March 2024 in Barcelona
  - ...

What would you like for future meetings?

# Live poll results – 34 answers

What would be your preferred format of future funders network meetings? E.g. workshop, speed date etc.

makers and payers      makers are present  
conference also for payors      physical meeting      online meeting  
online speed      **workshop**      person      open conference  
webinar      payers      Teams meetings  
government      Academia and patient orgs      policy makers      networking platforms  
great ideas      downstream barriers      workshop with payers

# Live poll results – 33 answers

Does an online meeting work for you?



# Live poll results – 33 answers



What do you take home from this workshop?

helpful solutions  
DR promising  
transnational collaboration  
challenges and solutions  
Great lot  
potential of this network  
need work solutions and ideas  
challenges  
policy challenges  
trail blazing common needs  
point common mission Aligned thinking  
connection with Remedi4all  
needs and intentions



# Live poll results – 24 answers

From your perspective, what should be the focus in future workshops?

Word cloud content:

- case
- Case studies
- market assessment
- MAH
- patent
- overcoming barriers
- policy and reimbursement
- discussion the feasibility
- favor of drug
- commercial interests
- case analysis
- repurposing Downstream barriers
- barriers - regulatory
- indication on label
- frameworks for collaboration
- business models
- time meetings
- Patient Engagement
- term sustainability



# Join the Drug Repurposing Funders Network



REMEDi4ALL IS ESTABLISHING A FUNDERS NETWORK.

**REMEDi4ALL** is establishing a funders network, led by **ZonMw** and in collaboration with the **Anticancer Fund**, dedicated to advancing Drug Repurposing initiatives.

**Are you a research funder involved or interested in drug repurposing?**

We invite you to share your experience and ideas within the International Drug Repurposing Funders Network. Our aim is to create a dynamic international network comprising diverse funders who are committed to driving Drug Repurposing forward. In this inclusive forum for discussion, we encourage you to share your funding perspective and actively engage in conversations surrounding policy matters and potential solutions to enhance the field. We hold annual meetings where we exchange best funding practices.



Heleen van der Meer



Dunja Huijbers

Contact us: [REMEDi4ALL@zonmw.nl](mailto:REMEDi4ALL@zonmw.nl)

 [Twitter](#)  [LinkedIn](#)  [Facebook](#)  [YouTube](#)  [Website](#)